Drugs
Conditions
News and resources
MIMS Supported Resources
In the treatment of neuropathic pain, efficacy has been demonstrated in studies in diabetic neuropathy, post-herpetic neuralgia and spinal cord injury.
In a clinical trial involving patients with central neuropathic pain, 22% of patients treated with pregabalin showed a 50% improvement in pain score, compared to 7% in the placebo group.
The incidence of adverse events when treating central neuropathic pain due to spinal cord injury was increased. This applied to general adverse events and CNS adverse events, particularly somnolence.
Lyrica is also indicated for the treatment of generalised anxiety disorder and adjunctive therapy in partial seizures.
In a clinical trial involving patients with central neuropathic pain, 22% of patients treated with pregabalin showed a 50% improvement in pain score, compared to 7% in the placebo group.
The incidence of adverse events when treating central neuropathic pain due to spinal cord injury was increased. This applied to general adverse events and CNS adverse events, particularly somnolence.
Lyrica is also indicated for the treatment of generalised anxiety disorder and adjunctive therapy in partial seizures.
